BMI1 Inhibition Improves Lesion Burden in Cerebral Cavernous Malformations

Circulation. 2024 Aug 27;150(9):738-741. doi: 10.1161/CIRCULATIONAHA.123.067438. Epub 2024 Aug 26.

Authors

Affiliations

¹ IFOM ETS, AIRC Institute of Molecular Oncology, Milan, Italy (M.V., M.M., C.M., F.Z., G.R., M.G.L., E.D., M.P.).
² Institute of Biochemistry and Biology, Potsdam University, Germany (V.-C.P., C.J.R., S.A.-S.).
³ Department of Immunology, Genetics and Pathology, Uppsala University, Sweden (M.A., P.U.M.).
⁴ Department of Medical Biotechnology and Translational Medicine, Università degli Studi di Milano, Italy (L.D., M.P.).

^# Contributed equally.

PMID: 39186529
DOI: 10.1161/CIRCULATIONAHA.123.067438

No abstract available

Keywords: cerebral cavernous malformations; endothelium drug therapy; polycomb repressive complexes.

Publication types

Letter

MeSH terms

Animals
Hemangioma, Cavernous, Central Nervous System* / pathology
Humans
Male
Mice
Polycomb Repressive Complex 1 / antagonists & inhibitors
Polycomb Repressive Complex 1 / genetics
Polycomb Repressive Complex 1 / metabolism

Substances

Polycomb Repressive Complex 1
BMI1 protein, human